Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

The influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher disease

  • Gervas-Arruga, J.
  • Cebolla, J.J.
  • De Blas, I.
  • Roca, M.
  • Pocovi, M.
  • Giraldo, P.
Gaucher disease, the most common lysosomal storage disorder, is caused by ß-glucocerebrosidase deficiency. Bone complications are the major cause of morbidity in patients with type 1 Gaucher disease (GD1). Genetic components strongly influence bone remodelling. In addition, chronic inflammation produced by Gaucher cells induces the production of several cytokines, which leads to direct changes in the bone remodelling process and can also affect the process indirectly through other immune cells. In this study, we analysed the association between bone mineral density (BMD), bone marrow burden score, and relevant genetic polymorphisms related to bone metabolism, as well as profiles of proinflammatory cytokines in a GD1 cohort. This study included 83 patients distributed according to bone status. BMD was measured with DXA and broadband ultrasound attenuation; bone marrow involvement was evaluated using MRI. We also analysed 26 SNPs located in 14 genes related to bone metabolism. To assess proinflammatory status, we analysed IL-4, IL-6, IL-7, IL-10, IL-13, MIP-1a, MIP-1ß, and TNFa in plasma samples from 71 control participants and GD1 patients. SNP genotype proportions and BMD differed significantly between ESRI c.453-397T>C and VDR c.1024+283G>A variants. We also observed significant associations between GD1 genotypes and bone affectation. When patients were stratified by spleen status, we observed significant correlations between non-/splenectomized groups and Spanish MRI (S-MRI) score. Across genotype proportions of non-/splenectomized patients and S-MRI, we observed significant differences in ESRI c.453-397T>C, VDR c.-83-25988G>A, and TNFRSF11B c.9C>G polymorphisms. We observed different significant proinflammatory profiles between control participants, treatment-naive patients, and patients on enzyme replacement therapy (ERT); between non-/splenectomized patients (between untreated and ERT-treated patients) and among those with differing GBA genotypes. The data suggest that patients with GD1 have increased susceptibility to developing bone disease owing to the coexistence of genetic variants, and that genetic background in GD1 is fundamental to regulate the impact of proinflammatory status on the development of bone disease.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Assessment of plasma chitotriosidase activity, CCL18/PARC concentration and NP-C suspicion index in the diagnosis of Niemann-Pick disease type C: A prospective observational study

  • Castro-Orós, I.
  • Irún, P.
  • Cebolla, J.J.
  • Rodriguez-Sureda, V.
  • Mallén, M.
  • Pueyo, M.J.
  • Mozas, P.
  • Dominguez, C.
  • Pocoví, M.
  • Bustamante, A.
  • Ortega, I.P.
  • Rivera, P.M.
  • Palomino, A.
  • Caceres, M.
  • Maestre, S.J.
  • Calderon, E.
  • Uranga, J.J.R.
  • Lorite, J.B.
  • Bustos, M.D.G.
  • Moreno, J.M.G.
  • Gonzalez, T.B.
  • Muñoz, A.
  • Acebal, M.R.
  • Medina, R.C.
  • Nieto, J.S.
  • Nuñez, E.
  • Sierra, C.
  • Campos, M.G.
  • Fernández de la Puebla, F.
  • Sepulveda, J.J.O.
  • Laso, E.L.
  • Maestre, A.
  • Martos, M.L.
  • Zafra, P.
  • Rosso, S.P.
  • Rosso, R.E.
  • Reyes, M.J.S.
  • Fernandez, L.A.
  • Moreno, A.O.
  • Pardo, C.C.
  • Martin, A.
  • Poveda, J.A.
  • Cantero, B.N.
  • Ruiz, P.G.
  • Rodrigo, M.
  • Posada, I.
  • Ferro, A.S.
  • Jesús, Hernandez Gallego
  • Villarejo, A.
  • San Martin, A.O.H.
  • Perez, A.G.
  • de Rivera, F.J.R.
  • Sanz, I.
  • Santos, F.
  • Gutierrez-Solana, L.
  • Fontan, C.
  • Duque, S.C.
  • Leal, R.M.
  • Gamez, J.
  • Santamaria, E.
  • del Toro, M.
  • Delgado, T.
  • Lorente, I.
  • Lleó, A.
  • Pagonabarraga, J.
  • Calvet, M.S.
  • Turón, E.
  • Moliner, E.
  • Pascual, B.
  • Almenar, C.
  • Torralba, A.O.
  • Floriach, R.M.
  • Nilda, Venegas Bernal
  • Villegas, M.D.L.
  • Giné, L.P.
  • Nomdedeu, B.
  • Martí, M.J.
  • Domenech, M.T.B.
  • Gascón, J.
  • Costa, J.
  • Fons, C.
  • Pineda, M.
  • Vidal, M.T.A.
  • Mira, E.
  • Tartari, J.P.
  • Aparici, R.C.
  • Sanchez, A.A.
  • Codony, M.B.
  • Alberti, M.A.
  • Ripoll, G.P.
  • Modol, R.
  • Genis, D.
  • Sivera, R.
  • Costa, J.F.V.
  • Martinez, I.
  • Smeyers, P.
  • Vila, T.
  • Casanova, B.
  • Miralles, F.C.P.
  • Serra, J.D.
  • Miñana, I.V.
  • Merino, C.V.
  • Garcia, R.
  • Jorda, R.M.S.
  • Clavel, J.
  • Santana, C.L.
  • Capablo, J.L.
  • Gazulla, J.
  • Padilla, P.
  • Loureiro, C.
  • Fdez-Balbuen, C.
  • Arias, M.
  • Rabuñal, M.J.
  • Sobrido, M.J.
  • Cia, M.T.
  • Yoldi, M.E.
  • Erro, M.E.
  • Fontes, A.
  • Axpe, I.R.
  • Sasieta, F.J.E.
  • Carlos, J.
  • Esteban, G.
  • Muñoz, J.A.S.
  • Espinosa, N.R.
  • Hernandez, M.A.
  • Martin, I.T.
  • Garrido, A.F.
  • Aporta, R.
  • Domingo, R.
  • Naranjo, I.C.
  • Gomez, M.A.R.
  • Ferrer, G.A.
Background: Niemann-Pick disease type C (NP-C) is a rare, autosomal recessive neurodegenerative disease caused by mutations in either the NPC1 or NPC2 genes. The diagnosis of NP-C remains challenging due to the non-specific, heterogeneous nature of signs/symptoms. This study assessed the utility of plasma chitotriosidase (ChT) and Chemokine (C-C motif) ligand 18 (CCL18)/pulmonary and activation-regulated chemokine (PARC) in conjunction with the NP-C suspicion index (NP-C SI) for guiding confirmatory laboratory testing in patients with suspected NP-C. Methods: In a prospective observational cohort study, incorporating a retrospective determination of NP-C SI scores, two different diagnostic approaches were applied in two separate groups of unrelated patients from 51 Spanish medical centers (n = 118 in both groups). From Jan 2010 to Apr 2012 (Period 1), patients with =2 clinical signs/symptoms of NP-C were considered ''suspected NP-C'' cases, and NPC1/NPC2 sequencing, plasma chitotriosidase (ChT), CCL18/PARC and sphingomyelinase levels were assessed. Based on findings in Period 1, plasma ChT and CCL18/PARC, and NP-C SI prediction scores were determined in a second group of patients between May 2012 and Apr 2014 (Period 2), and NPC1 and NPC2 were sequenced only in those with elevated ChT and/or elevated CCL18/PARC and/or NP-C SI =70. Filipin staining and 7-ketocholesterol (7-KC) measurements were performed in all patients with NP-C gene mutations, where possible. Results: In total across Periods 1 and 2, 10/236 (4%) patients had a confirmed diagnosis o NP-C based on gene sequencing (5/118 4.2%] in each Period): all of these patients had two causal NPC1 mutations. Single mutant NPC1 alleles were detected in 8/236 (3%) patients, overall. Positive filipin staining results comprised three classical and five variant biochemical phenotypes. No NPC2 mutations were detected. All patients with NPC1 mutations had high ChT activity, high CCL18/PARC concentrations and/or NP-C SI scores =70. Plasma 7-KC was higher than control cut-off values in all patients with two NPC1 mutations, and in the majority of patients with single mutations. Family studies identified three further NP-C patients. Conclusion: This approach may be very useful for laboratories that do not have mass spectrometry facilities and therefore, they cannot use other NP-C biomarkers for diagnosis.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease

  • Andrade-Campos, M.
  • Alfonso, P.
  • Irun, P.
  • Armstrong, J.
  • Calvo, C.
  • Dalmau, J.
  • Domingo, M.R.
  • Barbera, J.L.
  • Cano, H.
  • Fernandez-Galán, M.A.
  • Franco, R.
  • Gracia, I.
  • Gracia-Antequera, M.
  • Ibañez, A.
  • Lendinez, F.
  • Madruga, M.
  • Martin-Hernández, E.
  • O''Callaghan, M.D.M.
  • Del Soto, A.P.
  • Del Prado, Y.R.
  • Sancho-Val, I.
  • Sanjurjo, P.
  • Pocovi, M.
  • Giraldo, P.
Background: The enzymatic replacement therapy (ERT) availability for Gaucher disease (GD) has changed the landscape of the disease, several countries have screening programs. These actions have promoted the early diagnosis and avoided many complications in pediatric patients. In Spain ERT has been available since 1993 and 386 patients have been included in the Spanish Registry of Gaucher Disease (SpRGD). The aim of this study is to analyze the impact of ERT on the characteristics at time of diagnosis and initial complications in pediatric Gaucher disease patients. Aim: To analyze the impact of ERT on the characteristics at time of diagnosis and initial complications in pediatric Gaucher disease patients. Methods: A review of data in SpRGD from patients'' diagnosed before 18 years old was performed. The cohort was split according the year of diagnosis (=1994, cohort A; =1995, cohort B). Results: A total of 98 pediatric patients were included, GD1: 80, GD3: 18; mean age: 7.2 (0.17-16.5) years, 58 (59.2%) males and 40 (40.8%) females. Forty-five were diagnosed = 1994 and 53 = 1995. Genotype: N370S/N370S: 2 (2.0%), N370S/L444P: 27 (27.5%), N370S/other: 47 (48%), L444P/L444P: 7 (7.1%), L444P/D409H: 2 (2.0%), L444P/other: 3 (6.2%), other/other: 10 (10.2%). The mean age at diagnosis was earlier in patients diagnosed after 1995 (p < 0.001) and different between the subtypes, GD1: 8.2 (0.2-16.5) years and GD3: 2.8 (0.17-10.2) years (p < 0.001). There were more severe patients in the group diagnosed before 1994 (p = 0.045) carrying L444P (2), D409H (2), G377S (1), G195W (1) or the recombinant mutation. The patients'' diagnosed =1994 showed worse cytopenias, higher chance of bone vascular complications at diagnosis and previous spleen removal. The patients started ERT at a median time after diagnosis of 5.2 years [cohort A] and 1.6 years [cohort B] (p < 0.001). Conclusions: The early diagnosis of Gaucher disease in the era of ERT availability has permitted to reduce the incidence of severe and irreversible initial complication in pediatric patients, and this has permitted better development of these patients. This is the largest pediatric cohort from a national registry.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Assessment of plasma chitotriosidase activity, CCL18/PARC concentration and NP-C suspicion index in the diagnosis of Niemann-Pick disease type C, A prospective observational study

  • De Castro-Orós, Isabel
  • Irún, Pilar|||0000-0003-3392-7200
  • Cebolla, Jorge J.|||0000-0001-8727-9179
  • Rodríguez Sureda, Víctor|||0000-0003-4942-9249
  • Mallén, Miguel
  • Pueyo, María Jesús
  • Mozas, Pilar
  • Dominguez, Carmen
  • Pocoví, Miguel
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • Pérez Ortega, Irene
  • Mir, Pablo|||0000-0003-1656-302X
  • Palomino, Alfredo
  • Caceres, Maite
  • Jesús Maestre, Silvia|||0000-0002-1874-4628
  • Calderón, Enrique J.|||0000-0002-3166-5086
  • Rodríguez Uranga, Juan Jesus
  • Bautista Lorite, Juan
  • Gómez Bustos, Mª Dolores
  • García Moreno, Jose M.
  • Bermejo González, Teresa
  • Muñoz, Alfredo
  • Romero Acebal, Manuel
  • Calvo Medina, Rocío|||0000-0003-3322-4265
  • Serrano Nieto, Juliana
  • Nuñez, Esmeralda
  • Sierra, Carlos
  • Gil-Campos, Mercedes|||0000-0002-9007-0242
  • Fernández de la Puebla, Rafael
  • Ochoa Sepulveda, José
  • López Laso, Eduardo|||0000-0001-7732-6277
  • Maestre, Asunción
  • Ley Martos, Myriam|||0000-0001-8581-6786
  • Zafra, Pamela
  • Pantoja Rosso, Servando
  • Espinosa Rosso, Raul|||0000-0002-0876-8378
  • Salado Reyes, Mª Jesus
  • Arrabal Fernández, Luisa
  • Ortega Moreno, Angel
  • Carnero Pardo, C.|||0000-0003-3415-6727
  • Martin, Alejandro
  • Alom Poveda, Jordi
  • Nacimiento Cantero, Belén
  • García Ruiz, Pedro
  • Rodrigo, Maria
  • Posada, Ignacio
  • Sánchez Ferro, Alvaro
  • Hernández Gallego, Jesús
  • Villarejo-Galende, Alberto|||0000-0002-6834-7620
  • Herrero San Martin, Alejandro O.
  • García Perez, Asunción
  • Rodríguez de Rivera, Francisco Javier|||0000-0001-9008-7629
  • Sanz, Irene
  • Santos, Fernando
  • González Gutiérrez-Solana, Luis|||0000-0003-2890-4565
  • Fontan, Carmen
  • Cantero Duque, Susana
  • Martínez Leal, Rafael
  • Gamez Carbonell, Josep|||0000-0002-0426-1844
  • Santamaria, Esteve
  • Del Toro, Mireia|||0000-0002-8163-1853
  • Delgado, Tania
  • Lorente, Isabel
  • Lleó, Alberto|||0000-0002-2568-5478
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Suárez Calvet, Marc|||0000-0002-2993-569X
  • Turon Viñas, Eulalia|||0000-0001-6171-0282
  • Moliner Calderón, Elisenda|||0000-0001-5631-2888
  • Pascual Sedano, Berta María|||0000-0002-9298-8241
  • Almenar, Consuelo
  • Olivé Torralba, Anna
  • Misericordia Floriach, Robert
  • Venegas Bernal, Nilda
  • Lopez Villegas, Maria Dolores|||0000-0002-1023-1991
  • Planellas, Lluis|||0000-0002-0769-6675
  • Nomdedeu Tobella, Benet|||0000-0001-7831-4075
  • Martí Domenech, Maria Josep|||0000-0002-9872-7835
  • Bounjourno Domenech, Mª Teresa
  • Gascón, Jordi
  • Costa, Joan
  • Fons, Carmen|||0000-0001-7227-1350
  • Pineda, Mercedes
  • Abellán Vidal, Maria Teresa
  • Mira, Emili
  • Tartari, Juan Pablo
  • Castilla Aparici, Roser
  • Arévalo Sanchez, Antonio
  • Boix Codony, Marc
  • Alberti, María Antonia
  • Piñol-Ripoll, Gerard
  • Modol, Ramón
  • Genis, David
  • Sivera, Rafael|||0000-0003-2810-1180
  • Vázquez Costa, Juan Francisco
  • Martinez, Irene
  • Smeyers, Patricia
  • Vila, Tomas
  • Casanova, Bonaventura|||0000-0003-3806-925X
  • Pérez Miralles, Francisco Carlos
  • Dalmau Serra, Jaime
  • Vitoria Miñana, Isidro
  • Valero Merino, Caridad
  • Ribas Garcia, Raquel
  • Simó Jordá, Margarita
  • Clavel, Juana
  • Leiva Santana, Carlos
  • Capablo, Jose Luis
  • Gazulla, Jose
  • Padilla, Pablo
  • Loureiro, Carmen
  • Navarro Fernández-Balbuena, Carmen
  • Arias, Manuel|||0000-0002-4938-5402
  • Rabuñal, María José
  • Sobrido, María Jesús
  • Cia, María Teresa
  • Yoldi-Petri, María Eugenia
  • Erro, María Elena|||0000-0002-9707-4190
  • Fontes, Ariadna
  • Rouco Axpe, Idoia
  • Ezkurida Sasieta, Francisco Javier
  • Gómez Esteban, Juan Carlos|||0000-0002-4697-3890
  • Suárez Muñoz, Jose A.
  • Rodríguez Espinosa, Norberto
  • Hernández, Miguel A.
  • Tejera MartÍn, Ingrid
  • Fuentes Garrido, Alberto
  • Aporta, Rafael
  • Domingo, Rosario
  • Casado Naranjo, Ignacio
  • Ruíz Gómez, María Ángeles
  • Amer Ferrer, Guillermo
Niemann-Pick disease type C (NP-C) is a rare, autosomal recessive neurodegenerative disease caused by mutations in either the NPC1 or NPC2 genes. The diagnosis of NP-C remains challenging due to the non-specific, heterogeneous nature of signs/symptoms. This study assessed the utility of plasma chitotriosidase (ChT) and Chemokine (C-C motif) ligand 18 (CCL18)/pulmonary and activation-regulated chemokine (PARC) in conjunction with the NP-C suspicion index (NP-C SI) for guiding confirmatory laboratory testing in patients with suspected NP-C. In a prospective observational cohort study, incorporating a retrospective determination of NP-C SI scores, two different diagnostic approaches were applied in two separate groups of unrelated patients from 51 Spanish medical centers (n = 118 in both groups). From Jan 2010 to Apr 2012 (Period 1), patients with ≥2 clinical signs/symptoms of NP-C were considered 'suspected NP-C' cases, and NPC1/NPC2 sequencing, plasma chitotriosidase (ChT), CCL18/PARC and sphingomyelinase levels were assessed. Based on findings in Period 1, plasma ChT and CCL18/PARC, and NP-C SI prediction scores were determined in a second group of patients between May 2012 and Apr 2014 (Period 2), and NPC1 and NPC2 were sequenced only in those with elevated ChT and/or elevated CCL18/PARC and/or NP-C SI ≥70. Filipin staining and 7-ketocholesterol (7-KC) measurements were performed in all patients with NP-C gene mutations, where possible. In total across Periods 1 and 2, 10/236 (4%) patients had a confirmed diagnosis o NP-C based on gene sequencing (5/118 [4.2%] in each Period): all of these patients had two causal NPC1 mutations. Single mutant NPC1 alleles were detected in 8/236 (3%) patients, overall. Positive filipin staining results comprised three classical and five variant biochemical phenotypes. No NPC2 mutations were detected. All patients with NPC1 mutations had high ChT activity, high CCL18/PARC concentrations and/or NP-C SI scores ≥70. Plasma 7-KC was higher than control cut-off values in all patients with two NPC1 mutations, and in the majority of patients with single mutations. Family studies identified three further NP-C patients. This approach may be very useful for laboratories that do not have mass spectrometry facilities and therefore, they cannot use other NP-C biomarkers for diagnosis.